Professor of Ophthalmology, Vice Chair of International Research and Academic Affairs, Director of Ophthalmic Vascular Diagnostic & Research Program at Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, Department of OphthalmologyNew York, NY
Alon Harris, MS, PhD, FARVO
Professor Alon Harris is an internationally recognized expert and leader in the field of ocular blood flow and glaucoma. Dr. Harris’ academic specialties include novel approaches to glaucoma risk management, developing monitoring techniques for ocular hemodynamics and metabolism, mathematical modeling and artificial intelligence analysis of clinical and physiological biomarkers, investigating glaucoma theraputics, generic medications, and population-based studies.
Professor Harris has received over 6 million dollars in research funds from prestigious institutions including the National Institutes of Health (NIH), National Science Foundation (NSF), American Diabetes Association (ADA), and the National Eye Institute (NEI). In addition, Professor Harris has served as principal investigator on dozens of industry-sponsored clinical trials and has previously served as the Letzer Professor of Ophthalmology, Director of Clinical Research, and Chair of the Diversity Committee for the Department of Ophthalmology at Indiana University.
Dr. Harris has published over 368 peer-reviewed journal articles, 22 books and 69 book chapters. His 2021 Google Scholar h-index is: 72 and he has ranked in the top 12 glaucoma experts world-wide by Expertscape.
Dr. Harris has received numerous national and international awards including the Sam Rothberg Glaucoma Award; the William and Mary Greve International Research Scholar Award from the Research to Prevent Blindness organization; the Glenn W. Irwin Jr., MD., Experience Excellence Recognition Award; Edmund Benjamin Spaeth Oration Award for Outstanding Clinical Research; American Academy of Ophthalmology Achievement Award and Letzter Endowed Chair of Ophthalmology.
Professor Harris holds two patents (others pending) in the United States: 1) Novel Treatment of Macular Edema; and 2) Method to Increase Retinal and Optic Nerve Head Blood Flow.
In addition, Professor Harris’ is an internationally recognized entrepreneur in the field of ophthalmology. He has extensive experience in navigating, fundraising, and bridging the transition from academic discovery to marketplace solutions. Dr. Harris has previously served as consultant to major pharmaceutical companies including Merck, Pfizer, Alcon, and Allergan. Dr. Harris is sought after for his expertise in start-up considerations and he is the co-founder of AdOM, a novel ophthalmic medical imaging company developing modalities for assessment of dry eye disease. Professor Harris also currently serves as Chairman of the Board for XLVision, and is a board member and/or senior consultant for Phileas Pharma, CIPLA, Qlairs, Oxymap, Nano Retina, and QuLent.